Haihe Bio received 100 million RMB in Series B financing

Haihe Bio is a comprehensive service provider of pharmaceutical regulations consulting and testing, focusing on medical devices, preclinical testing of drugs, animal experiments and registration regulations consulting, and is committed to providing high-quality services for well-known domestic and foreign medical enterprises in the product registration process. Recently, it won the B round invest.

This article is reproduced from: https://www.itjuzi.com/investevent/13124462
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment